Table 2.
Results from analysis of the (a) eight HTR3A and (b) 13 HTR3B single-nucleotide polymorphisms (SNPs) in antipsychotic-associated weight gain in schizophrenia patients of European ancestry.
| (a)
| |||||
|---|---|---|---|---|---|
| SNP | Genotypes | Number of patients | Mean percentage weight change | Standard Deviation of percentage weight change | Genotype P (all antipsychotics/clozapine or olanzapine only) |
|
| |||||
| rs10789980_A1G2 | A/A | 29 | 4.83 | 5.77 | 0.099/0.651 |
| A/G | 72 | 3.32 | 5.15 | ||
| G/G | 44 | 5.13 | 5.01 | ||
|
| |||||
| rs1150226_T1C2 | T/T | 1 | 3.56 | 0.970/0.801 | |
| T/C | 24 | 4.17 | 5.57 | ||
| C/C | 124 | 4.12 | 5.27 | ||
|
| |||||
| rs1062613_T1C2 | T/T | 6 | 3.27 | 6.56 | 0.759/0.948 |
| T/C | 54 | 4.01 | 5.24 | ||
| C/C | 89 | 4.25 | 5.28 | ||
|
| |||||
| rs1150222_T1G2 | T/T | 2 | 6.79 | 12.03 | 0.829/0.817 |
| T/G | 43 | 3.87 | 4.79 | ||
| G/G | 104 | 4.18 | 5.40 | ||
|
| |||||
| rs2276302_A1G2 | A/A | 70 | 3.88 | 5.25 | 0.699/0.621 |
| A/G | 69 | 4.38 | 5.31 | ||
| G/G | 10 | 4.09 | 5.72 | ||
|
| |||||
| rs11214789_T1C2 | T/T | 102 | 4.09 | 5.37 | 0.957/0.932 |
| T/C | 43 | 4.19 | 4.96 | ||
| C/C | 3 | 4.53 | 9.37 | ||
|
| |||||
| rs10891613_A1T2 | A/A | 61 | 4.23 | 5.60 | 0.978/0.467 |
| A/T | 74 | 4.05 | 4.91 | ||
| T/T | 15 | 3.82 | 5.91 | ||
|
| |||||
| rs11608102_T1G2 | T/T | 134 | 4.06 | 5.29 | 0.402/0.574 |
| T/G | 15 | 4.71 | 5.35 | ||
| G/G | |||||
| (b)
| |||||
|---|---|---|---|---|---|
| SNP | Genotypes | Number of patients | Mean percentage weight change | Standard Deviation of percentage weight change | Genotype P (all antipsychotics/clozapine or olanzapine only) |
|
| |||||
| rs3891484_T1C2 | T/T | 112 | 4.18 | 5.36 | 0.125/0.317 |
| T/C | 33 | 4.61 | 4.96 | ||
| C/C | 4 | −1.29 | 2.67 | ||
|
| |||||
| rs10789970_T1C2 | T/T | 31 | 2.84 | 4.64 | 0.296/0.748 |
| T/C | 69 | 4.45 | 5.78 | ||
| C/C | 49 | 4.48 | 4.88 | ||
|
| |||||
| rs11214763_A1G2 | A/A | 5 | 6.09 | 7.99 | 0.255/0.600 |
| A/G | 52 | 4.91 | 4.78 | ||
| G/G | 92 | 3.58 | 5.37 | ||
|
| |||||
| rs3758987_A1G2 | A/A | 80 | 4.17 | 5.54 | 0.062/0.071 |
| A/G | 56 | 4.67 | 5.13 | ||
| G/G | 11 | 0.60 | 3.03 | ||
|
| |||||
| rs1176744_T1G2 | T/T | 74 | 3.80 | 5.34 | 0.099/0.044 |
| T/G | 61 | 5.03 | 5.40 | ||
| G/G | 13 | 1.76 | 3.70 | ||
|
| |||||
| rs3782025_T1C2 | T/T | 46 | 4.11 | 5.64 | 0.962/0.834 |
| T/C | 78 | 4.19 | 5.29 | ||
| C/C | 25 | 3.97 | 4.74 | ||
|
| |||||
| rs1672717_T1C2 | T/T | 62 | 3.54 | 4.82 | 0.431/0.410L |
| T/C | 66 | 4.70 | 6.00 | ||
| C/C | 21 | 4.03 | 3.99 | ||
|
| |||||
| rs2011249_T1C2 | T/T | 8 | −0.40 | 2.20 | 0.047/0.206 |
| T/C | 45 | 4.56 | 4.94 | ||
| C/C | 96 | 4.30 | 5.47 | ||
|
| |||||
| rs6589400_A1C2 | A/A | 93 | 4.37 | 4.81 | 0.477F/0.663 |
| A/C | 45 | 3.44 | 6.36 | ||
| C/C | 8 | 4.52 | 4.85 | ||
|
| |||||
| rs11606194_T1C2 | T/T | 130 | 3.98 | 5.25 | 0.444/0.289 |
| T/C | 18 | 4.98 | 5.65 | ||
| C/C | 1 | 7.42 | |||
|
| |||||
| rs1176758_T1C2 | T/T | 62 | 3.80 | 5.00 | 0.614F/0.439 |
| T/C | 72 | 4.57 | 5.80 | ||
| C/C | 15 | 3.33 | 3.61 | ||
|
| |||||
| rs7129190_A1C2 | A/A | 45 | 3.96 | 5.17 | 0.727/0.426 |
| A/C | 74 | 4.36 | 5.50 | ||
| C/C | 30 | 3.81 | 5.03 | ||
|
| |||||
| rs7945619_A1G2 | A/A | 4 | 2.82 | 5.58 | 0.313F/0.607F |
| A/G | 35 | 3.25 | 6.31 | ||
| G/G | 109 | 4.46 | 4.94 | ||
c
p-values from ANCOVA (comparison among the three genotype groups) of percent weight change with sex, treatment duration, baseline weight, and clozapine/olanzapine (yes/no) as covariates.
L
significant Levene’s Test.
F
significant Lack of Fit Test.
p-values in bold font <0.05.